Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects the motor system. It is characterized by bradykinesia, rigidity, tremor, and postural instability. This article aims to provide a comprehensive overview of PD, including its pathogenesis, clinical manifestations, diagnostic criteria, and recent advancements in treatment.
PD is caused by the progressive loss of dopamine-producing cells in the substantia nigra, a part of the brain that controls movement. This leads to a reduction in striatal dopamine, causing the characteristic motor symptoms of PD. Non-motor symptoms such as autonomic dysfunction, cognitive impairment, and mood disorders are also common.
The diagnosis of PD is primarily clinical, based on the presence of bradykinesia and either rigidity, rest tremor, or both. The Movement Disorder Society (MDS) has proposed new diagnostic criteria that incorporate non-motor symptoms and dopamine transporter (DAT) imaging, providing a more accurate diagnosis.
The mainstay of PD treatment remains dopamine replacement therapy, with levodopa being the most effective medication. However, recent advancements have led to the development of new therapeutic strategies. Deep brain stimulation (DBS), for instance, has shown significant benefits in managing motor symptoms in advanced PD. Additionally, research is ongoing into disease-modifying therapies that could slow or halt disease progression.
Understanding PD's complex pathophysiology and clinical manifestations is crucial for its effective management. While current treatment options can manage symptoms, they do not slow disease progression. However, ongoing research into disease-modifying therapies offers hope for future advancements. As healthcare professionals, staying abreast of these developments is key to providing the best possible care for our patients.
1.
Tumor characteristics found to differ for melanomas in children, teens and young adults
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
Screening for Early Therapy-Related Cancer Susceptibility
3.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
4.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
5.
Reducing Modifiable Childhood Cancer Exposure Risks
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Importance of Cancer Screening and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation